How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city
Author:
Publisher
Oxford University Press (OUP)
Subject
General Medicine,Epidemiology
Link
http://academic.oup.com/ije/article-pdf/39/1/244/2094765/dyp213.pdf
Reference28 articles.
1. Reform of how health care is paid for in China: challenges and opportunities
2. Drugs for preventing cardiovascular disease in China
3. Rationing by Patient Choice
4. Can it work? Does it work? Is it worth it?
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China;Journal of Medical Economics;2020-01-25
2. Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial;BMJ Evidence-Based Medicine;2019-08-31
3. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study;PLOS Medicine;2015-08-04
4. Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang;Trials;2013-10-25
5. Characteristics of High Risk People with Cardiovascular Disease in Chinese Rural Areas: Clinical Indictors, Disease Patterns and Drug Treatment;PLoS ONE;2013-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3